Stockreport

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Summit Therapeutics Inc.  (SMMT) 
Last summit therapeutics inc. earnings: 6/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre
PDF Ivonescimab alone or combined with chemotherapy led to intracranial responses among 34% of patients with brain metastases at baseline – 23% achieved a complete responseA [Read more]